GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (NAS:BTAI) » Definitions » PS Ratio

BioXcel Therapeutics (BioXcel Therapeutics) PS Ratio : 54.79 (As of Apr. 28, 2024)


View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, BioXcel Therapeutics's share price is $2.63. BioXcel Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.05. Hence, BioXcel Therapeutics's PS Ratio for today is 54.79.

The historical rank and industry rank for BioXcel Therapeutics's PS Ratio or its related term are showing as below:

BTAI' s PS Ratio Range Over the Past 10 Years
Min: 43.96   Med: 282.5   Max: 4394
Current: 54.79

During the past 8 years, BioXcel Therapeutics's highest PS Ratio was 4394.00. The lowest was 43.96. And the median was 282.50.

BTAI's PS Ratio is ranked worse than
80.54% of 992 companies
in the Biotechnology industry
Industry Median: 8.85 vs BTAI: 54.79

BioXcel Therapeutics's Revenue per Sharefor the three months ended in Dec. 2023 was $0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.05.

During the past 12 months, the average Revenue per Share Growth Rate of BioXcel Therapeutics was 261.50% per year.

Back to Basics: PS Ratio


BioXcel Therapeutics PS Ratio Historical Data

The historical data trend for BioXcel Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics PS Ratio Chart

BioXcel Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - - - 1,652.31 62.77

BioXcel Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,652.31 933.00 185.00 58.84 62.77

Competitive Comparison of BioXcel Therapeutics's PS Ratio

For the Biotechnology subindustry, BioXcel Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioXcel Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioXcel Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's PS Ratio falls into.



BioXcel Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

BioXcel Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=2.63/0.048
=54.79

BioXcel Therapeutics's Share Price of today is $2.63.
BioXcel Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


BioXcel Therapeutics  (NAS:BTAI) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


BioXcel Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioXcel Therapeutics (BioXcel Therapeutics) Business Description

Traded in Other Exchanges
Address
555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Executives
Vimal Mehta director, officer: CEO, President, Secretary 780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Richard I Steinhart officer: Chief Financial Officer 125 ELM STREET, NEW CANAAN CT 06840
Javier Rodriguez officer: SEE REMARKS C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Krishnan Nandabalan director, 10 percent owner 228 VILLAGE POND ROAD, GUILFORD CT 06437
Akrati Agarwal 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Michael James Aiello 10 percent owner 10 TEMPLETON ROAD, WALLINGFORD CT 06492
Krunal Dilip Patel 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Alka Sood 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Pardeep Kumar Sood 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Vipin Agarwal 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Rashmi Agarwal 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Jatin Markand Patel 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Bina Jatin Patel 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Diwakar Jain 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Anita Jain 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437

BioXcel Therapeutics (BioXcel Therapeutics) Headlines

From GuruFocus